ONCAlert | Upfront Therapy for mRCC

HCC VIEW MORE >>

An ongoing phase IIa clinical trial has demonstrated the safety and efficacy of milciclib maleate at 6 months in patients with unresectable or metastatic hepatocellular carcinoma who were resistant or intolerant to sorafenib.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.